Your browser doesn't support javascript.
loading
International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV.
Singer, Susanne; Amdal, Cecilie Delphin; Hammerlid, Eva; Tomaszewska, Iwona M; Castro Silva, Joaquim; Mehanna, Hisham; Santos, Marcos; Inhestern, Johanna; Brannan, Christine; Yarom, Noam; Fullerton, Amy; Pinto, Monica; Arraras, Juan I; Kiyota, Naomi; Bonomo, Pierluigi; Sherman, Allen C; Baumann, Ingo; Galalae, Razvan; Fernandez Gonzalez, Loreto; Nicolatou-Galitis, Ourania; Abdel-Hafeez, Zeinab; Raber-Durlacher, Judith; Schmalz, Claudia; Zotti, Paola; Boehm, Andreas; Hofmeister, Dirk; Krejovic Trivic, Sanja; Loo, Suat; Chie, Wei-Chu; Bjordal, Kristin; Brokstad Herlofson, Bente; Grégoire, Vincent; Licitra, Lisa.
Affiliation
  • Singer S; Division of Epidemiology and Health Services Research, Institute of Medical Biostatistics, Epidemiology, and Informatics (IMBEI), University Medical Centre of Johannes Gutenberg University, Mainz, Germany.
  • Amdal CD; Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Hammerlid E; Department of Otolaryngology and Head and Neck Surgery, Sahlgrenska University Hospital, Gothenburg University, Gothenburg, Sweden.
  • Tomaszewska IM; Department of Medical Didactics, Jagiellonian University Medical College, Krakow, Poland.
  • Castro Silva J; Department of Otolaryngology, Head and Neck Surgery, Instituto Português de Oncologia Francisco Gentil do Porto, Porto, Portugal.
  • Mehanna H; Institute of Head and Neck Studies and Education, University of Birmingham, Birmingham, United Kingdom.
  • Santos M; Radiation Oncology Department, Brasilia University Hospital, Brasilia, Brazil.
  • Inhestern J; Clinic of Otorhinolaryngology, Jena University Hospital, Jena, Germany.
  • Brannan C; Lynda Jackson Macmillan Centre, East & North Hertfordshire NHS Trust incorporating Mount Vernon Cancer Centre, Northwood, United Kingdom.
  • Yarom N; Oral Medicine Unit, Sheba Medical Center, Tel-Hashomer, Israel and School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Fullerton A; Department of Speech, Language and Hearing Sciences, College of Public Health and Health Professions, University of Florida, Gainesville, Florida.
  • Pinto M; Supportive Care Department, Istituto Nazionale Tumori -IRCCS- Fondazione G. Pascale, Naples, Italy.
  • Arraras JI; Oncology Departments, Complejo Hospitalario de Navarra, Pamplona, Spain.
  • Kiyota N; Department of Medical Oncology and Hematology, Kobe University Hospital Cancer Center, Kobe, Japan.
  • Bonomo P; Radiation Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
  • Sherman AC; Behavioral Medicine Division, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Baumann I; Department of Otolaryngology, Head and Neck Surgery, University of Heidelberg, Heidelberg, Germany.
  • Galalae R; Department of Radiation Oncology, EVK Gelsenkirchen, University Duisburg-Essen, Gelsenkirchen, Germany.
  • Fernandez Gonzalez L; Research and Teaching Unit, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile.
  • Nicolatou-Galitis O; Clinic of Hospital Dentistry, Dental Oncology Unit, School of Dentistry, National and Kapodistrian University of Athens, Athens, Greece.
  • Abdel-Hafeez Z; Department of Clinical Oncology, Ain Shams-University, Cairo, Egypt.
  • Raber-Durlacher J; Department of Oral and Maxillofacial Surgery, Amsterdam University Medical Center (location AMC) and Department of Oral Medicine ACTA, University of Amsterdam and VU University, Amsterdam, The Netherlands.
  • Schmalz C; Department of Radiation Therapy, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Zotti P; Department of Psychology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  • Boehm A; Department of Otolaryngology Head and Neck Surgery, St. Georg Hospital, Leipzig, Germany.
  • Hofmeister D; Department of Medical Psychology, University Hospital Leipzig, Leipzig, Germany.
  • Krejovic Trivic S; Clinic of Otorhinolaryngology and Maxillofacial Surgery, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  • Loo S; Department of Oncology, Colchester Hospital University NHS Foundation Trust, Colchester, United Kingdom.
  • Chie WC; Department of Family Medicine, Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
  • Bjordal K; Department of Research Support Services, Oslo University Hospital, and University of Oslo, Oslo, Norway.
  • Brokstad Herlofson B; Department of Oral Surgery and Oral Medicine, University of Oslo, and Department of Otorhinolaryngology - Head and Neck Surgery Division for Head, Neck and Reconstructive Surgery, Oslo University Hospital, Oslo, Norway.
  • Grégoire V; Radiation Oncology Dept & Center for Molecular Imaging and Experimental Radiotherapy, Université Catholique de Louvain and St-Luc University Hospital, Brussels, Belgium.
  • Licitra L; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, and University of Milan, Milan, Italy.
Head Neck ; 41(6): 1725-1737, 2019 06.
Article in En | MEDLINE | ID: mdl-30636188
ABSTRACT

BACKGROUND:

We validated the new European Organisation for Research and Treatment of Cancer Quality of Life Head and Neck Module (EORTC QLQ-HN43).

METHODS:

We enrolled 812 patients with head and neck cancer from 18 countries. Group 1 completed the questionnaire before therapy, and 3 and 6 months later. In group 2 (survivors), we determined test-retest reliability using intraclass correlation coefficients (ICC). Internal consistency was assessed using Cronbach's Alpha, the scale structure with confirmatory factor analysis, and discriminant validity with known-group comparisons.

RESULTS:

Cronbach's alpha was >0.70 in 10 of the 12 multi-item scales. All standardized factor loadings exceeded 0.40. The ICC was >0.70 in all but two scales. Differences in scale scores between known-groups were >10 points in 17 of the 19 scales. Sensitivity to change was found to be sufficient in 18 scales.

CONCLUSIONS:

Evidence supports the reliability and validity of the EORTC QLQ-HN43 as a measure of quality of life.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Surveys and Questionnaires / Head and Neck Neoplasms Type of study: Diagnostic_studies / Observational_studies / Qualitative_research / Risk_factors_studies Aspects: Patient_preference Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Head Neck Journal subject: NEOPLASIAS Year: 2019 Document type: Article Affiliation country: Alemania

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Surveys and Questionnaires / Head and Neck Neoplasms Type of study: Diagnostic_studies / Observational_studies / Qualitative_research / Risk_factors_studies Aspects: Patient_preference Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Head Neck Journal subject: NEOPLASIAS Year: 2019 Document type: Article Affiliation country: Alemania